Optical Genome Mapping in Hematological Malignancies

Recruiting now

Conditions studied: MDS, ALL, Other Hematologic Malignant Neoplasms

In brief

Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer

Key facts

Study ID

NCT05009537

Run by

University Hospital, Brest

People needed

200

Starts

2021-09-01

Expected to finish

2026-09-01

Last updated by the study team

2021-08-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Minor/Major Patients
• Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made.
• No objection made or consent given

You may not qualify if…

• Patients under judicial protection (guardianship, curatorship, ...),
• Refusal to participate

Where it is running

• CHRU de Brest — Brest, France (enrolling)
• CH Morlaix, service d'hémato clinique — Morlaix, France (enrolling)
• CHIC, service d'hémato clinique — Quimper, France (enrolling)
• CH St Brieuc, service d'hémato clinique — Saint-Brieuc, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.